DelveInsight’s “Chronic Insomnia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Insomnia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Chronic Insomnia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Insomnia: An Overview
Insomnia is the most common sleep disorder with huge socio-economic costs. According to the third edition of the International Classification of Sleep Disorders (ICSD-3), insomnia is characterized by difficulty in either initiating sleep, maintaining sleep continuity, or poor sleep quality. These symptoms occur despite the presence of adequate opportunity and circumstance for sleep and result in daytime dysfunction. According to the third edition of the International Classification of Sleep Disorder, an individual suffers from chronic insomnia disorder if the sleep disturbances occur at least three times a week and have been present for the last 3 months.
Various studies worldwide have shown the prevalence of insomnia in 10–30% of the population, some even as high as 50–60%. It is common in older adults, females, and people with medical and mental ill-health. Chronic insomnia can adversely affect health, quality of life, and academic performance, increase the risk of motor vehicle accidents, decrease productivity at work, cause irritability, and increase daytime sleepiness.
Insomnia is also considered a contributing risk factor for medical problems like cardiovascular diseases, chronic pain syndrome, depression, anxiety, diabetes, obesity, and asthmaIt is an easy-to-diagnose condition with many self-answerable questionnaires for aid, yet goes unrecognized in a significant number of patients coming to the outpatient department with other comorbid conditions.
Chronic Insomnia Market Key Facts
-
The market size of Chronic Insomnia in the seven major markets was USD 314.2 million in 2020.
-
The total number of prevalent cases of Chronic Insomnia in the 7MM countries was 5,585,000+ in 2020.
-
In the coming years, the Chronic Insomnia market is set to change due to the rising awareness of the disease and the favorable environment for new anti-infective modalities; which would expand the market’s size to enable drug manufacturers to penetrate the market more.
-
A few major players in the global Chronic Insomnia market are actively working in the late phase of clinical development, such as Janssen Research & Development and others aiming to launch drugs for the treatment of Chronic Insomnia.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Chronic Insomnia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Chronic Insomnia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chronic Insomnia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Chronic Insomnia Epidemiology, Segmented as –
-
Diagnosed Prevalent Cases of Insomnia in the 7MM (2019–2032)
-
Diagnosed Prevalent Cases of Chronic Insomnia in the 7MM (2019–2032)
-
Treatable Cases of Chronic Insomnia in the 7MM (2019–2032)
-
Age-specific Diagnosed Prevalent Cases of Chronic Insomnia in the 7MM (2019–2032)
-
Gender-specific Diagnosed Prevalent Cases of Chronic Insomnia in the 7MM (2019–2032)
Chronic Insomnia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Insomnia market or expected to be launched during the study period. The analysis covers the Chronic Insomnia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Insomnia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Chronic Insomnia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/chronic-insomnia-market
The Leading Players in the Chronic Insomnia Therapeutics Market Include:
-
Eisai Inc.
-
Merck & Co.
-
Idorsia Pharmaceuticals
-
Janssen Research & Development
-
Minerva Neurosciences
-
Sequential Medicine Ltd.
And Many Others
Chronic Insomnia Emerging and Marketed Drugs Covered in the Report Include:
-
Daridorexant: Idorsia Pharmaceuticals
-
Seltorexant: Janssen Research & Development/Minerva Neurosciences
-
Dayvigo (lemborexant): Eisai Inc.
-
Belsomra (Suvorexant): Merck & Co.
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/chronic-insomnia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Insomnia Competitive Intelligence Analysis
4. Chronic Insomnia Market Overview at a Glance
5. Chronic Insomnia Disease Background and Overview
6. Chronic Insomnia Patient Journey
7. Chronic Insomnia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Chronic Insomnia Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Insomnia Unmet Needs
10. Key Endpoints of Chronic Insomnia Treatment
11. Chronic Insomnia Marketed Products
12. Chronic Insomnia Emerging Drugs and Latest Therapeutic Advances
13. Chronic Insomnia Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Insomnia Market Outlook (In US, EU5, and Japan)
16. Chronic Insomnia Access and Reimbursement Overview
17. KOL Views on the Chronic Insomnia Market
18. Chronic Insomnia Market Drivers
19. Chronic Insomnia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/chronic-insomnia-market
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/